Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease.
Powles
Tom
T
Stebbing
Justin
J
Montoto
Silvia
S
Nelson
Mark
M
Gazzard
Brian
B
Orkin
Chloe
C
Webb
Andy
A
Bower
Mark
M
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005871:Castleman Disease / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006566:Herpesviridae Infections / Q000150:complications / Q000188:drug therapy*; D019288:Herpesvirus 8, Human; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D000069283:Rituximab; D019562:Viral Load
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab